Fiche société
Vanderbilt-Ingram Cancer Center
Traitements, essais et publications liés.
Traitements1programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
1| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Cytarabine 100 MG/MLThe goal of this clinical trial is to reduce the duration of ICANS and incidence of G3 or great ICANS in participants who receive axi-cel. The main questions the study aims to answer are: Efficacy of IT therapy to reduce high-grade ICANS in participants who receive axi-cel in NHL compared to historical experience. Researchers will compare Axi-cel to Brexu-cel see if there will be a reduction in ICANS when compared to historical experience. | Cancer | Phase 2 | À vérifier | United States | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Hydrocortisone | Cancer | Phase 2 | NCT07763210 | Lazarus: IT Therapy for ICANS | NOT_YET_RECRUITING |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||